Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Study Identifier:
CCD-01535BA0-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Asthma
Study Drug
- Drug: Foster 100/6mg NEXThaler
- Drug: Foster 100/6mg pMDI
Date
Oct 2017 - Dec 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Healthy Volunteers
No
Protocol Summary
The purpose of this study is to demonstrate the non-inferiority of Foster 100/6mg NEXThaler versus Foster 100/6mg pMDI in terms of pulmonary function in asthmatic patients, as well as the effect of the test treatments in terms of additional lung function parameters and clinical outcome measures. The purpose is also to assess the safety and tolerability.
Study Locations
Location
Status
Location
Chiesi Clinical Trial site 15641
Hefei, Anhui, China
Status
N/A
Location
Chiesi Clinical Trial site 15682
Beijing, Beijing, China, 100000
Status
N/A
Location
Chiesi Clinical Trial site 15663
Beijing, Beijing, China, 101100
Status
N/A
Location
Chiesi Clinical Trial site 15662
Foshan, Guangdong, China
Status
N/A
Location
Chiesi Clinical Trial site 15671
Guangzhou, Guangdong, China, 5100150
Status
N/A
Location
Chiesi clinical Trial Site 15610
Guangzhou, Guangdong, China, 510120
Status
N/A